15

A method of administering a compound of the formula

- wherein X and Y are the same or different halo group; R is H or 5 lower alkyl; and pharmaceutically acceptable salts thereof; together with a chemotherapeutic agent.
 - A method according to Claim 1 wherein the chemotherapeutic agent 2. is selected from the group consisting of cisplatin; cyclophosphamide; 5-fluorouracil, doxorubicin and taxol.
 - A method according to Claim 1 wherein the compound is selected 3. from the group consisting of:

$$\begin{array}{c|c} & H & H & O & H & CO_2R \\ \hline & N & N & O & H & CO_2R \\ & O & O & Br \end{array}$$

A method according to Claim 3 wherein the chemotherapeutic agent
is selected from the group consisting of cisplatin,
cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.

10

5. A method of treating or preventing a neoplasia disease comprising administering to a mammal in need of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:

$$\begin{array}{c|c} & H & H & O \\ \hline N & N & O \\ \hline N & N & O \\ \hline OH & N & OH \\ \end{array}$$

wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof; together with a chemotherapeutic agent.

- 6. A method according to Claim 5 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
- 7. A method according to Claim 5 wherein the compound is selected from the group consisting of

$$\begin{array}{c|c} & H & H & O & H & CO_2R \\ \hline & N & N & OH & CI & I \\ & & OH & CI & I \\ \end{array}$$

Br

$$\begin{array}{c|c} & H & H & O \\ \hline N & N & O \\ \hline N & N & O \\ \hline O & O \\ \hline O & O \\ \hline \end{array}$$

- 8. A method according to Claim 7 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
 - 9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1, a chemotherapeutic agent and a pharmaceutically acceptable carrier.

- A method according to Claim 5 wherein the neoplasia disease is tumor metastasis.
- 11. A method according to Claim 5 wherein the neoplasia disease treated is solid tumor growth.
 - 12. A method according to Claim 5 wherein the condition treated is angiogenesis.
- 13. A method according to Claim 5 wherein the neoplasia disease is humoral hypercalcemia of malignancy.